Von Willebrand's Disease Clinical Trial
Verified date | December 2001 |
Source | Office of Rare Diseases (ORD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding
time, in vivo recovery, and circulating half-life of the infused factor in patients with von
Willebrand's disease.
II. Assess the safety of von Willebrand factor in these patients.
Status | Completed |
Enrollment | 10 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
PROTOCOL ENTRY CRITERIA: - von Willebrand's disease |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Center for Research Resources (NCRR) | University of North Carolina |
Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, Thompson AR, White GC 2nd. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol. 1996 Sep;94(4):740-5. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02061033 -
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
|
N/A |